Fiorenzo Villani Buys 10,382 Shares of Portage Biotech (NASDAQ:ALP) Stock

Portage Biotech Inc. (NASDAQ:ALP) insider Fiorenzo Villani purchased 10,382 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was acquired at an average cost of $4.07 per share, for a total transaction of $42,254.74. Following the completion of the acquisition, the insider owned 34,601 shares in the company, valued at $140,826.07. This represents a 42.87% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Fiorenzo Villani also recently made the following trade(s):

• On Wednesday, September 16th, Fiorenzo Villani bought 4,265 shares of Portage Biotech stock. The shares were bought at an average price of $4.05 per share, with a total value of $17,273.25.
• On Tuesday, September 15th, Fiorenzo Villani purchased 7,900 shares of Portage Biotech stock. The stock was bought at an average price of $4.15 per share, for a total transaction of $32,785.00.
• On Monday, September 14th, Fiorenzo Villani acquired 2,000 shares of Portage Biotech stock. The shares were bought at an average cost of $4.16 per share, with a total value of $8,320.00.
• On Wednesday, September 9th, Fiorenzo Villani bought 7,000 shares of Portage Biotech stock. The stock was purchased at an average cost of $5.07 per share, for a total transaction of $35,490.00.

Portage Biotech Price Performance

Portage Biotech stock traded up $0.40 during midday trading on Thursday, reaching $4.50. 53,755 shares of the stock traded hands, compared to its average volume of 232,688. The stock has a market cap of $6.97 million, a P/E ratio of -0.01 and a beta of 0.54. The stock’s fifty day moving average is $9.78 and its 200-day moving average is $14.39. The company has a quick ratio of 0.31, a current ratio of 0.31 and a debt-to-equity ratio of 0.01. Portage Biotech Inc. has a 12 month low of $3.20 and a 12 month high of $690.00.

Portage Biotech (NASDAQ:ALP) last posted its earnings results on Thursday, July 16th. The company reported $23.75 EPS for the quarter. The firm had revenue of $0.05 million for the quarter. As a group, equities research analysts anticipate that Portage Biotech Inc. will post -14 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on ALP shares. Weiss Ratings restated a “sell (e+)” rating on shares of Portage Biotech in a research report on Friday, July 24th. Zacks Research raised shares of Portage Biotech to a “hold” rating in a research note on Tuesday, August 18th. Wall Street Zen raised Portage Biotech to a “hold” rating in a research note on Saturday, September 12th. Finally, HC Wainwright began coverage on Portage Biotech in a research report on Monday, August 17th. They issued a “neutral” rating and a $12.50 price objective on the stock. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Portage Biotech currently has a consensus rating of “Reduce” and an average price target of $12.50.

About Portage Biotech

Portage Biotech (NASDAQ:ATON) is a biotechnology company focused on acquiring, developing and advancing therapeutic candidates and platform technologies. The company concentrates its development efforts primarily in areas such as oncology, immunology/inflammation and infectious disease, seeking to move programs from discovery and preclinical stages into clinical development through subsidiary companies and collaborative arrangements.

Portage structures its operations to support a diversified pipeline, advancing both small molecules and biologics by funding preclinical research, conducting clinical trials, and managing regulatory interactions.